AU2019299358B2 - Methods of producing recombinant proteins - Google Patents

Methods of producing recombinant proteins

Info

Publication number
AU2019299358B2
AU2019299358B2 AU2019299358A AU2019299358A AU2019299358B2 AU 2019299358 B2 AU2019299358 B2 AU 2019299358B2 AU 2019299358 A AU2019299358 A AU 2019299358A AU 2019299358 A AU2019299358 A AU 2019299358A AU 2019299358 B2 AU2019299358 B2 AU 2019299358B2
Authority
AU
Australia
Prior art keywords
batch
cells
culture
cell
enriched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019299358A
Other languages
English (en)
Other versions
AU2019299358A1 (en
Inventor
Michael C. BORYS
Zhengjian Li
Jun Tian
JianLin XU
Andrew YONGKY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67470657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019299358(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2019299358A1 publication Critical patent/AU2019299358A1/en
Application granted granted Critical
Publication of AU2019299358B2 publication Critical patent/AU2019299358B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2019299358A 2018-07-03 2019-07-02 Methods of producing recombinant proteins Active AU2019299358B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862693606P 2018-07-03 2018-07-03
US62/693,606 2018-07-03
PCT/US2019/040298 WO2020010080A1 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins

Publications (2)

Publication Number Publication Date
AU2019299358A1 AU2019299358A1 (en) 2021-02-18
AU2019299358B2 true AU2019299358B2 (en) 2026-04-02

Family

ID=67470657

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019299358A Active AU2019299358B2 (en) 2018-07-03 2019-07-02 Methods of producing recombinant proteins

Country Status (23)

Country Link
US (2) US20210253996A1 (https=)
EP (2) EP3818078B1 (https=)
JP (3) JP7419273B2 (https=)
KR (2) KR20250153311A (https=)
CN (1) CN112839954A (https=)
AU (1) AU2019299358B2 (https=)
CA (1) CA3104684A1 (https=)
DK (1) DK3818078T3 (https=)
EA (1) EA202092904A1 (https=)
ES (1) ES2976708T3 (https=)
FI (1) FI3818078T3 (https=)
HR (1) HRP20240584T1 (https=)
HU (1) HUE066560T2 (https=)
IL (2) IL324666A (https=)
LT (1) LT3818078T (https=)
MX (1) MX2020013633A (https=)
PL (1) PL3818078T3 (https=)
PT (1) PT3818078T (https=)
RS (1) RS65472B1 (https=)
SG (1) SG11202012582QA (https=)
SI (1) SI3818078T1 (https=)
SM (1) SMT202400173T1 (https=)
WO (1) WO2020010080A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK181991B1 (en) * 2021-11-11 2025-05-15 Dsm Ip Assets Bv Combined fermentation process for producing one or more human milk oligosaccharide(s) (hmo(s)) in escherichia coli
WO2023242238A1 (en) * 2022-06-15 2023-12-21 UCB Biopharma SRL Cell culture processes
EP4339274B1 (en) 2022-09-13 2025-03-26 Sartorius Stedim Biotech GmbH Method for operating a bioprocess installation for production of a bioproduct
KR20240172522A (ko) * 2023-06-01 2024-12-10 (주)알테오젠 지속형 호르몬 수용체 길항제의 생산 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015186075A1 (en) * 2014-06-03 2015-12-10 Lupin Limited Cell culture process for producing a protein

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE68919361T2 (de) 1988-06-21 1995-05-24 Genentech Inc Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2193136T3 (es) 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2108566T3 (es) 1993-12-10 1997-12-16 Genentech Inc Procedimientos para diagnosticar alergias y para seleccionar agentes terapeuticos antialergicos.
WO1995019181A1 (en) 1994-01-18 1995-07-20 Genentech, Inc. A METHOD OF TREATMENT OF PARASITIC INFECTION USING IgE ANTAGONISTS
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0941344B1 (en) 1996-11-27 2004-05-19 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
ES2293682T5 (es) 1997-05-15 2011-11-17 Genentech, Inc. Anticuerpo anti-apo2.
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
ES2309012T3 (es) 1999-10-29 2008-12-16 Genentech, Inc. Composiciones del anticuerpo anti-psca y a sus procedimientos contra celulas cancerigenas que expresen psca.
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
PT2837680T (pt) * 2011-07-01 2020-04-17 Amgen Inc Cultura celular de mamífero
AU2015269365A1 (en) * 2014-06-04 2016-12-15 Amgen Inc. Methods for harvesting mammalian cell cultures
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015095809A1 (en) * 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
WO2015186075A1 (en) * 2014-06-03 2015-12-10 Lupin Limited Cell culture process for producing a protein

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GAGNON, M. ET AL., 'High-End pH-Controlled Delivery of Glucose Effectively Suppresses Lactate Accumulation In CHO Fed-Batch Cultures', Biotechnology and Bioengineering, Vol. 108, No. 6, June, 2011, pages 1328-1337 *
LU F. ET AL: "Automated dynamic fed-batch process and media optimization for high productivity cell culture process development", BIOTECHNOLOGY AND BIOENGINEERING, vol. 110, no. 1, 1 January 2013, pages 191 - 205 *
SAUER, P.W. ET AL., 'A High-Yielding, Generic Fed-Batch Cell Culture Process for Production of Recombinant Antibodies', Biotechnology and Bioengineering, Vol. 67, No. 5, March 5, 2000, pages 585 - 597 *
SETH G. ET AL., 'Development of a New Bioprocess Scheme Using Frozen Seed Train Intermediates to Initiate CHO Cell Culture Manufacturing Campaigns', Biotechnology and Bioengineering, Vol. 110, No. 5, May, 2013, pages 1376-1385 *
XU S. ET AL: "Bioreactor productivity and media cost comparison for different intensified cell culture processes", BIOTECHNOLOGY PROGRESS, vol. 33, no. 4, 28 January 2017, pages 867 - 878 *

Also Published As

Publication number Publication date
US20210253996A1 (en) 2021-08-19
IL324666A (en) 2026-01-01
CA3104684A1 (en) 2020-01-09
IL279782A (en) 2021-03-01
CN112839954A (zh) 2021-05-25
WO2020010080A1 (en) 2020-01-09
PL3818078T3 (pl) 2024-04-29
EP4368699A2 (en) 2024-05-15
BR112020025623A2 (pt) 2021-03-23
IL279782B1 (en) 2026-01-01
SMT202400173T1 (it) 2024-07-09
JP2024050590A (ja) 2024-04-10
PT3818078T (pt) 2024-04-18
JP7419273B2 (ja) 2024-01-22
ES2976708T3 (es) 2024-08-07
EP3818078A1 (en) 2021-05-12
AU2019299358A1 (en) 2021-02-18
EP3818078B1 (en) 2024-02-28
FI3818078T3 (fi) 2024-05-14
DK3818078T3 (da) 2024-05-21
MX2020013633A (es) 2021-03-25
US20250171732A1 (en) 2025-05-29
JP2021529527A (ja) 2021-11-04
EP4368699A3 (en) 2024-09-11
KR20250153311A (ko) 2025-10-24
SI3818078T1 (sl) 2024-05-31
KR20210027427A (ko) 2021-03-10
HRP20240584T1 (hr) 2024-07-19
KR102870511B1 (ko) 2025-10-15
SG11202012582QA (en) 2021-01-28
LT3818078T (lt) 2024-04-25
RS65472B1 (sr) 2024-05-31
JP2026048825A (ja) 2026-03-17
HUE066560T2 (hu) 2024-08-28
EA202092904A1 (ru) 2021-04-22

Similar Documents

Publication Publication Date Title
US20250171732A1 (en) Methods of producing recombinant proteins
US20220315887A1 (en) Methods of improving protein productivity in fed-batch cell cultures
JP2026032016A (ja) 哺乳動物細胞培養プロセス
JP2017521075A (ja) 細胞バンクの解凍復元を改善するためのｐＨ調整
US11242510B2 (en) Mammalian cells devoid of lactate dehydrogenase activity
JP2018531619A (ja) 灌流様式において組換えたんぱく質の生産プロファイルを調節する方法
US12486525B2 (en) Methods for increasing productivity of therapeutic proteins
US20090142805A1 (en) High expression cell line that eliminates gene amplification
EA048403B1 (ru) Способы получения рекомбинантных белков
BR112020025623B1 (pt) Método para a produção, em grande escala, de um polipeptídeo recombinante de interesse
US20250115666A1 (en) Cell culture methods for producing therapeutic proteins
WO2026006162A2 (en) B vitamin modulation
HK40002355A (en) Methods of decreasing trisulfide bonds during recombinant production of polypeptides